Abstract
In a randomized, double-blind trial for metastatic prostate cancer (Stage D2), 603 men received leuprolide, a gonadotropin-releasing hormone analog that inhibits the release of gonadotropins, coupled with either placebo or flutamide, a nonsteroidal antiandrogen that inhibits the binding of androgens to the cell nucleus. The 303 men receiving androgen blockade with leuprolide and flutamide demonstrated a longer progression-free survival (16.9 vs. 13.9 months, P = 0.039) and an increased median length of survival (35.0 vs. 27.9 months, P = 0.035). In the subgroup of men with minimal disease and good performance status, the advantages of maximal androgen blockade were more pronounced. It is concluded that combined androgen blockade with leuprolide and flutamide was more effective than leuprolide alone for patients with metastatic cancer of the prostate. The therapeutic benefits, although greatest in patients with minimum disease, need to be evaluated in a prospective, randomized fashion in trials specifically designed for men with minimal disease and good performance status. Exploratory analyses using the black race as an explanatory variable were also performed. Black race is associated with shorter survival times and is also ass...Continue Reading
References
Nov 16, 1985·British Medical Journal·J WaxmanR T Oliver
Mar 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A EisenbergerM A Friedman
Aug 1, 1987·Endocrine Reviews·G R CunhaY Sugimura
Apr 1, 1988·American Journal of Clinical Oncology·H AzizR J Macchia
Jun 1, 1986·Biology of Reproduction·Y SugimuraJ R Brody
Jan 1, 1986·The Prostate·J T IsaacsJ Scheres
Nov 1, 1973·Cancer·D P Byar
Nov 15, 1984·The New England Journal of Medicine·UNKNOWN Leuprolide Study Group
Jun 1, 1983·British Journal of Urology·C R Woodhouse, E P O'Donoghue
Apr 1, 1980·Cancer·William W ScottPatrick C Walsh
Citations
Nov 20, 1998·The Journal of Pharmacy and Pharmacology·S A BahshwanM Ahmadi
Nov 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles J Ryan, Eric J Small
Sep 4, 2019·Journal of Comparative Effectiveness Research·Maobai LiuWei Jiang
Dec 15, 1993·Cancer·S SuciuL Denis
Feb 1, 1993·Cancer·J P DrozS Culine
Jan 19, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M RoachP R Carroll
Jan 5, 2000·Seminars in Surgical Oncology·M K Brawer
Jun 28, 2006·Prostate Cancer and Prostatic Diseases·N D JamesC Luscombe
Sep 24, 2010·Cancer·Joel PicusUNKNOWN Cancer and Leukemia Group B
Feb 2, 2018·Oncology Letters·Hongmei XiaWeihua Yin
Sep 25, 1997·The Journal of Urology·A PatelJ B deKernion
Nov 9, 2000·BJU International·D HroudaA G Dalgleish
May 5, 2000·The Cochrane Database of Systematic Reviews·B SchmittT Wilt
May 21, 2010·American Journal of Men's Health·Gayathri SridharJohn D Roberts
Nov 7, 2006·The Journal of Urology·Charles J Ryan, Eric J Small
Oct 22, 2008·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Kelly K CurtisMichael K Gornet
Nov 7, 2019·Reviews on Recent Clinical Trials·Muhammed RashidKrishna Undela
Aug 19, 2010·American Journal of Men's Health·Chris MetcalfeYoav Ben-Shlomo
Oct 1, 1996·The Prostate·S O AsbellM Rotman
Nov 7, 1998·British Journal of Urology·D HroudaA G Dalgleish
Sep 7, 2007·Cancer Immunology, Immunotherapy : CII·M-C LabartheM A Whelan
Jun 1, 1994·Postgraduate Medicine·Craig A Winkel
Mar 1, 1996·Cancer Treatment Reviews·M N MiddlemanW D Figg
Nov 7, 1998·Cancer Treatment Reviews·A J Dowling, I F Tannock